Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended...

20
Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of global and public health University of Bergen [email protected] Stephane Verguet Department of Global Health University of Washington

description

Objective To evaluate the expected financial protection and health gains of two publicly financed child health programs in Ethiopia, pneumonia treatment and pneumococcal vaccination Averages will be spread across income groups

Transcript of Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended...

Page 1: Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.

Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis

Kjell Arne Johansson Department of global and public health

University of [email protected]

Stephane VerguetDepartment of Global Health

University of Washington

Page 2: Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.

Plan• Burden of pneomococcal disease and pneumonia in Ethiopia

• Health benefits across income groups

• Costs of public finance

• Income equivalent equity weights

• Private expenditures averted

• Financial protection

Page 3: Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.

Objective

• To evaluate the expected financial protection and health gains of two publicly financed child health programs in Ethiopia, pneumonia treatment and pneumococcal vaccination

• Averages will be spread across income groups

Page 4: Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.

DISEASE BURDEN AND DEMANDBACKGROUND

Page 5: Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.
Page 6: Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.

Disease burden and income distribution in Ethiopia

Page 7: Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.

Utilization of health services

Page 8: Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.
Page 9: Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.

Total costs of public finance of both interventions (close to 40% coverage)

Page 10: Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.

Deaths avertedper 1,000,000 US$:

PCV (0.2 US$): 3010PCV (3.5 US$): 540Antibiotics: 560

Page 11: Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.

Income equivalent health gains- distributive weights applied

Ref: Fleurbaey M et al. Health Econ. 2012

Page 12: Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.

Fair evaluation of PCV/antibiotics- income equivalent weights applied

Equivalent lives saved per 1,000,000 US$:

PCV (0.2 US$): 3010 3060 (2%)Antibiotics: 560 660 (18%)

Page 13: Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.

Financial protection

Page 14: Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.

Household expenditures avertedper 1,000,000 US$:

PCV: 180,000 US$Antibiotics: 160,000 US$

Page 15: Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.

Utility curve for financial protection

U(y) = (y^(1-r) / (1-r)

Ref. Finkelstein A., McKnight R. Journal of Public Economics. 2008; McClellan M, Skinner J, Journal of Public Economics. 2006;

Page 16: Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.

Expected value of incomeE(y) = (1 - I0(y))y + I0(y) (y - Ctreatment)Expected value of utilityEu(y) = (1 - I0(y))u(y) + I0(y) u(y - Ctreatment)Insurance value / certainty equivalentV(y) = E(y) – u-1[Eu(y)]

Page 17: Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.

Financial risk protection

Page 18: Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.

Health gains & financial protection - per $1M spent

Page 19: Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.

Expected distribution of health gains & financial protection (per $1M spent)

Page 20: Public finance of pneumococcal vaccine and pneumonia treatment in Ethiopia: - an extended cost-effectiveness analysis Kjell Arne Johansson Department of.

Summary• Health distribution

PCV saves most lives. Equivalent health gains improves the expected utilities the most for pneumonia treatment by giving more weight to health benefits to the poor

• Financial protectionPneumonia treatment improves financial protection the most, especially for the poor

• Normative problemSave the most lives (PCV) vs. improving financial protection the most (pneumonia treatment)